Cargando…

Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy

BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing C...

Descripción completa

Detalles Bibliográficos
Autores principales: Godaly, Gabriela, Carlsson, Ola, Broman, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792612/
https://www.ncbi.nlm.nih.gov/pubmed/26985370
http://dx.doi.org/10.1093/ckj/sfv133
_version_ 1782421275390509056
author Godaly, Gabriela
Carlsson, Ola
Broman, Marcus
author_facet Godaly, Gabriela
Carlsson, Ola
Broman, Marcus
author_sort Godaly, Gabriela
collection PubMed
description BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. METHODS: We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid. RESULTS: Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid–base parameters were detected between the groups. CONCLUSIONS: In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed.
format Online
Article
Text
id pubmed-4792612
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47926122016-03-16 Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy Godaly, Gabriela Carlsson, Ola Broman, Marcus Clin Kidney J Acute Kidney Injury BACKGROUND: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. METHODS: We retrospectively analysed 112 patients treated with CRRT at Skåne University Hospital, Sweden. The control group was treated with Hemosol(®) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium(®) (phosphate; n = 76) as dialysis fluid and Hemosol(®) B0 as replacement fluid. RESULTS: Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid–base parameters were detected between the groups. CONCLUSIONS: In this larger cohort, we could confirm that Phoxilium(®) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed. Oxford University Press 2016-04 2015-12-19 /pmc/articles/PMC4792612/ /pubmed/26985370 http://dx.doi.org/10.1093/ckj/sfv133 Text en © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Acute Kidney Injury
Godaly, Gabriela
Carlsson, Ola
Broman, Marcus
Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title_full Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title_fullStr Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title_full_unstemmed Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title_short Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
title_sort phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy
topic Acute Kidney Injury
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792612/
https://www.ncbi.nlm.nih.gov/pubmed/26985370
http://dx.doi.org/10.1093/ckj/sfv133
work_keys_str_mv AT godalygabriela phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy
AT carlssonola phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy
AT bromanmarcus phoxiliumreduceshypophosphataemiaandmagnesiumsupplementationduringcontinuousrenalreplacementtherapy